6 completed, 3 terminated, 3 unknown, 2 recruiting. 3 Not applicable, 3 Phase 2, 3 Phase 3, 1 Early Phase 1, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 3 | Completed 1, Recruiting 1, Terminated 1 |
| Phase 2 | 3 | Completed 2, Recruiting 1 |
| Phase 3 | 3 | Completed 1, Terminated 1, Unknown 1 |
| Early Phase 1 | 1 | Terminated 1 |
| Phase 1 | 1 | Completed 1 |
Follow Anti-Retroviral Agents: new trials by email Literature Review of Anti-Retroviral Agents trials Research Report on Anti-Retroviral Agents
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Vitamin D3 Supplementation in Patients With HIV: Effects on Interleukin-6 Levels and CD4 Counts Vitamin D3, Antiretroviral (ARV) medications - Human Immunodeficiency Virus (HIV) | Not applicable | Completed | Universitas Sebelas Maret | 20 | 2025-06-01 | 2026-07-15 |
| Project neuroARTEMIS ARTEMIS, Contingency management for Antiretroviral (ARV) adherence - Stimulant Use, Human Immunodeficiency Virus (HIV) | Not applicable | Recruiting | Wake Forest University Health Sciences | 189 | 2025-04-29 | 2026-09-03 |
| UB-421 in Combination With Optimized Background Regimen in Patients With Multi-drug Resistant HIV-1 Infection UB-421, Antiretroviral (ARV) - HIV-1 Infection | Phase 3 | Unknown | United BioPharma | 50 | 2023-12-01 | 2023-04-24 |
| Clinical Trial to Evaluate the Efficacy and Safety of Codivir® in Addition to Standard Antiretroviral Treatment for HIV Infection in Antiretroviral-naïve Participants ICF, Eligibility Assessment, Demographic data - HIV, HIV Infection | Phase 2 | Recruiting | Code Pharma | 40 | 2023-07-20 | 2024-11-06 |
| The Lymphoid Tissue Pharmacology of Antiretroviral Drugs Anti-HIV Agents - HIV Infection | Withdrawn | University of Nebraska | 2023-03-25 | 2023-08-24 | ||
| Improving HIV-1 Control in Africa With Long Acting Antiretrovirals Cabotegravir/Rilpivirine, Antiretroviral - HIV-1-infection | Phase 3 | Completed | MRC/UVRI and LSHTM Uganda Research Unit | 540 | 2022-12-08 | 2026-10-09 |
| Reducing Antiretroviral Treatments Antiretroviral - HIV-1-infection | Phase 3 | Terminated | ANRS, Emerging Infectious Diseases | 360 | 2019-11-27 | 2026-06-08 |
| Evaluating the Pharmacokinetics, Safety, and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-Infected Children and Adolescents Doravirine (DOR), Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF), Antiretroviral (ARV) medications - HIV Infections | Phase 1 / Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 55 | 2018-07-02 | 2023-02-14 |
| Gut Microbiota and Immune Recovery Anti-Retroviral Agents - HIV-1-infection | Unknown | Shanghai Public Health Clinical Center | 80 | 2017-12-01 | 2018-03-27 | |
| Prevention and Treatment Continuum for Youth at HIV Risk, Acutely Infected and With Established HIV Infection Antiretrovirals - Human Immunodeficiency Virus | Completed | University of California, Los Angeles | 101 | 2017-08-01 | 2025-03-25 | |
| The Impact and Cost-effectiveness of Safer Conception Strategies for HIV-discordant Couples (SAFER) PrEP (Truvada), Antiretrovirals, Semen washing - HIV Infections | Completed | University of California, San Francisco | 46 | 2017-03-13 | 2019-09-30 | |
| Early Administration of Romidepsin and 3BNC117 in Treatment-naïve HIV Patients Starting ART Romidepsin, 3BNC117, Antiretrovirals - Hiv | Phase 2 | Completed | Aarhus University Hospital | 60 | 2017-01-20 | 2025-04-18 |
| COMO: Cognition Study With HIV+ Patients (CTNPT 015) Change in antiretrovirals - HIV - Human Immunodeficiency Virus, Cognitive Symptoms | Early Phase 1 | Terminated | Marie-Josée Brouillette | 19 | 2011-06-01 | 2016-03-16 |
| Bone Mineral Density (BMD) in HIV Infection BMD Measurement, antiretrovirals - Osteopenia, Osteoporosis | Not applicable | Terminated | University Hospital, Strasbourg, France | 44 | 2003-03-01 | 2025-09-26 |
| Cohorte Nationale VIH-2 Antiretroviral - HIV-2 Infection | Unknown | ANRS, Emerging Infectious Diseases | 1185 | 1994-01-01 | 2020-12-08 |
Acquired Immunodeficiency Syndrome (6) · HIV Infections (5) · Anxiety Disorders (1) · Bone Diseases, Metabolic (1) · Depression (1) · Neurobehavioral Manifestations (1) · Osteoporosis (1) · Substance-Related Disorders (1) · Virus Diseases (1)
ANRS, Emerging Infectious Diseases (2) · Aarhus University Hospital (1) · Code Pharma (1) · MRC/UVRI and LSHTM Uganda Research Unit (1) · Marie-Josée Brouillette (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Shanghai Public Health Clinical Center (1) · United BioPharma (1) · Universitas Sebelas Maret (1) · University Hospital, Strasbourg, France (1) · University of California, Los Angeles (1) · University of California, San Francisco (1) · University of Nebraska (1) · Wake Forest University Health Sciences (1)
France (3) · United States (3) · South Africa (2) · Brazil (1) · Canada (1) · China (1) · Denmark (1) · Indonesia (1) · Kenya (1) · Thailand (1) · Uganda (1) · United Kingdom (1) · Zimbabwe (1)
Adam W Carrico, PhD (1) · Ann Melvin, MD, MPH (1) · Christina S Meade, PhD (1) · Courtney V Fletcher, PharmD (1) · Felix Mhlanga, MBChB, MMed (1) · Fiona Cresswell, MBChB, PhD (1) · Joelle M Brown, PhD, MPH (1) · Karin Nielsen, M.D. (1) · Tim Schacker, MD (1)
PMID 33046066, PMID 36253609, PMID 36963004, PMID 41040645, PMID 42874104
2015 (1), 2019 (1), K01MH100994 (1), R01AI124965 (1), R01DA061952 (1)